Evaluate：2026年全球医药前瞻性报告（英文版）

can stumble. Take Lilly’s retatrutide, the so-called “triple G” asset that ranks as one of the sector’s most highly valued R&D projects in this report. Emerging phase 3 data shows patients unhappy with the dramatic levels of weight loss and high levels of gastric side effects. Retatrutide is far from written off. But with much competition in the metabolic pipeline and many moving parts, the market incumbent cannot be assumed to own the best-inclass follow-on. There are plenty of other co